Cell-type-specific proteome and interactome: Using HIV-1 Tat as a test case

Expert Review of Proteomics

Volumn 6, Issue 5, 2009, Pages 515-526

  Van Duyne, Rachel ^a   Kehn Hall, Kylene ^a   Carpio, Lawrence ^a   Kashanchi, Fatah ^a  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

Epigenetics; HIV 1; Interactome; Proteomics; Tat; Transcription

Indexed keywords

BINDING PROTEIN; PROTEOME; TRANSACTIVATOR PROTEIN;

CD4+ T LYMPHOCYTE; CELL TYPE; CELLULAR DISTRIBUTION; CYTOTOXIC T LYMPHOCYTE; EPIGENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MACROPHAGE; MONOCYTE; NONHUMAN; PROTEIN LOCALIZATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; REVIEW; VIRUS CELL INTERACTION; VIRUS REPLICATION; VIRUS TRANSCRIPTION;

EPIGENESIS, GENETIC; GENE PRODUCTS, TAT; HIV-1; HUMANS; PROTEIN BINDING; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEOME; TRANSCRIPTION, GENETIC; VIRAL TROPISM;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 70350438051     PISSN: 14789450     EISSN: 17448387     Source Type: Journal    
DOI: 10.1586/epr.09.73     Document Type: Review

References (118)

1. Ptak RG et al. Cataloguing the HIV type 1 human protein interaction network. AIDS Res. Hum. Retroviruses 24(12), 1497-1502 (2008). •• Unique compilation and database of all human cellular proteins that have been documented to interact with HIV-1 viral proteins.
2. Alexaki A, Liu Y, Wigdahl B. Cellular reservoirs of HIV-1 and their role in viral persistence. Curr. HIV Res. 6(5), 388-400 (2008).
3. + monocyte subset is more permissive to infection and preferentially harbors HIV-1 in vivo. J. Immunol. 178(10), 6581-6589 (2007).
4. Lambotte O, Taoufik Y, de Goër MG et al. Detection of infectious HIV in circulating monocytes from patients on prolonged highly active antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 23(2), 114-119 (2000). (Pubitemid 30316835)
5. McElrath MJ Pruett JE, Cohn ZA. Mononuclear phagocytes of blood and bone marrow: comparative roles as viral reservoirs in human immunodeficiency virus type 1 infections. Proc. Natl Acad. Sci. USA 86(2), 675-679 (1989).
6. McElrath MJ Steinman RM, Cohn ZA. Latent HIV-1 infection in enriched populations of blood monocytes and T cells from seropositive patients. J. Clin. Invest. 87(1), 27-30 (1991).
7. Mikovits JA, Lohrey NC, Schulof R, Courtless J, Ruscetti FW. Activation of infectious virus from latent human immunodeficiency virus infection of monocytes in vivo. J. Clin. Invest. 90(4), 1486-1491 (1992).
8. Minagar A, Commins D, Alexander JS et al. NeuroAIDS: characteristics and diagnosis of the neurological complications of AIDS. Mol. Diagn. Ther. 12(1), 25-43 (2008). (Pubitemid 351281697)
9. King JE, Eugenin EA, Buckner CM, Berman JW. HIV tat and neurotoxicity. Microbes Infect. 8(5), 1347-1357 (2006).
10. D'Aversa TG, Eugenin EA, Berman JW. NeuroAIDS: contributions of the human immunodeficiency virus-1 proteins Tat and gp120 as well as CD40 to microglial activation. J. Neurosci. Res. 81(3), 436-446 (2005).
11. Ma M, Geiger JD, Nath A. Characterization of a novel binding site for the human immunodeficiency virus type 1 envelope protein gp120 on human fetal astrocytes. J. Virol. 68(10), 6824-6828 (1994). (Pubitemid 24294942)
12. Clapham PR, Weber JN, Whitby D et al. Soluble CD4 blocks the infectivity of diverse strains of HIV and SIV for T cells and monocytes but not for brain and muscle cells. Nature 337(6205), 368-370 (1989). (Pubitemid 19043500)
13. Lavi E, Kolson DL, Ulrich AM, Fu L, González-Scarano F. Chemokine receptors in the human brain and their relationship to HIV infection. J. Neurovirol. 4(3), 301-311 (1998). (Pubitemid 28260714)
14. Orenstein JM, Meltzer MS, Phipps T, Gendelman HE. Cytoplasmic assembly and accumulation of human immunodeficiency virus types 1 and 2 in recombinant human colony-stimulating factor-1-treated human monocytes: an ultrastructural study. J. Virol. 62(8), 2578-2586 (1988). (Pubitemid 18193848)
15. Deneka M, Pelchen-Matthews A, Byland R, Ruiz-Mateos E, Marsh M. In macrophages, HIV-1 assembles into an intracellular plasma membrane domain containing the tetraspanins CD81, CD9, and CD53. J. Cell. Biol. 177(2), 329-341 (2007). (Pubitemid 46658643)
16. Weinberg JB, Matthews TJ, Cullen BR, Malim MH. Productive human immunodeficiency virus type 1 (HIV-1) infection of nonproliferating human monocytes. J. Exp. Med. 174(6), 1477-1482 (1991).
17. Kinoshita S, Su L, Amano M, Timmerman LA, Kaneshima H, Nolan GP. The T cell activation factor NF-ATc positively regulates HIV-1 replication and gene expression in T cells. Immunity 6(3), 235-244 (1997). (Pubitemid 27148590)
18. Yang, Z, Engel JD. Human T cell transcription factor GATA-3 stimulates HIV-1 expression. Nucleic Acids Res. 21(12), 2831-2836 (1993). (Pubitemid 23220433)
19. Henderson AJ, Calame KL. CCAAT/enhancer binding protein (C/EBP) sites are required for HIV-1 replication in primary macrophages but not CD4(+) T cells. Proc. Natl Acad. Sci. USA 94(16), 8714-8719 (1997).
20. Leea ES, Sarmab D, Zhoua H, Henderson AJ. CCAAT/enhancer binding proteins are not required for HIV-1 entry but regulate proviral transcription by recruiting coactivators to the long-terminal repeat in monocytic cells. Virology 299(1), 20-31 (2002).
21. Felzien LK, Woffendin C, Hottiger MO, Subbramanian RA, Cohen EA, Nabel GJ. HIV transcriptional activation by the accessory protein, VPR, is mediated by the p300 co-activator. Proc. Natl Acad. Sci. USA 95(9), 5281-5286 (1998). (Pubitemid 28208589)
22. Sawaya BE, Khalili K, Gordon J, Taube R, Amini S. Cooperative interaction between HIV-1 regulatory proteins Tat and Vpr modulates transcription of the viral genome. J. Biol. Chem. 275(45), 35209-35214 (2000). (Pubitemid 30832539)
23. + T cells. J. Exp. Med. 194(10), 1407-1419 (2001).
24. Dong C, Kwas C, Wu L. Transcriptional restriction of human immunodeficiency virus type 1 gene expression in undifferentiated primary monocytes. J. Virol. 83(8), 3518-3527 (2009).
25. Berro R, Kehn K, de la Fuente C et al. Acetylated Tat regulates human immunodeficiency virus type 1 splicing through its interaction with the splicing regulator p32. J. Virol. 80(7), 3189-3204 (2006).
26. Chiu YL, Ho CK, Saha N, Schwer B, Shuman S, Rana TM. Tat stimulates cotranscriptional capping of HIV mRNA. Mol. Cell. 10(3), 585-597 (2002). (Pubitemid 35284175)
27. Kuciak M, Gabus C, Ivanyi-Nagy R et al. The HIV-1 transcriptional activator Tat has potent nucleic acid chaperoning activities in vitro. Nucleic Acids Res. 36(10), 3389-3400 (2008). (Pubitemid 351859006)
28. Bennasser Y, Le SY, Benkirane M, Jeang KT. Evidence that HIV-1 encodes an siRNA and a suppressor of RNA silencing. Immunity 22(5), 607-619 (2005). (Pubitemid 40719196)
29. Bennasser Y, Jeang KT. HIV-1 Tat interaction with Dicer: requirement for RNA. Retrovirology 3, 95 (2006). (Pubitemid 46189735)
30. Peruzzi F. The multiple functions of HIV-1 Tat: proliferation versus apoptosis. Front Biosci. 11, 708-717 (2006). (Pubitemid 43258174)
31. Kalantari P, Harandi OF, Hankey PA, Henderson AJ. HIV-1 Tat mediates degradation of RON receptor tyrosine kinase, a regulator of inflammation. J. Immunol. 181(2), 1548-1555 (2008).
32. Minghetti L, Visentin S, Patrizio M, Franchini L, Ajmone-Cat MA, Levi G. Multiple actions of the human immunodeficiency virus type-1 Tat protein on microglial cell functions. Neurochem. Res. 29(5), 965-978 (2004). (Pubitemid 39011346)
33. Niikura M, Dornadula G, Zhang H et al. Mechanisms of transcriptional transactivation and restriction of human immunodeficiency virus type I replication in an astrocytic glial cell. Oncogene 13(2), 313-322 (1996). (Pubitemid 26334863)
34. Berkhout B, Gatignol A, Rabson AB, Jeang KT. TAR-independent activation of the HIV-1 LTR: evidence that tat requires specific regions of the promoter. Cell 62(4), 757-767 (1990). •• HIV-1 Tat can interact with the viral LTR directly to induce transcription via a TAR-independent mechanism. (Pubitemid 20275715)
35. Calnan BJ, Biancalana S, Hudson D, Frankel AD. Analysis of arginine-rich peptides from the HIV Tat protein reveals unusual features of RNA-protein recognition. Genes Dev. 5(2), 201-210 (1991). (Pubitemid 21905945)
36. Nekhai S, R.Shukla R, Kumar A. A human primary T-lymphocyte-derived human immunodeficiency virus type 1 Tat-associated kinase phosphorylates the C-terminal domain of RNA polymerase II and induces CAK activity. J. Virol. 71(10), 7436-7441 (1997). (Pubitemid 27391683)
37. García-Martínez LF, Mavankal G, Neveu JM, Lane WS, Ivanov D, Gaynor RB. Purification of a Tat-associated kinase reveals a TFIIH complex that modulates HIV-1 transcription. EMBO J. 16(10), 2836-2850 (1997). (Pubitemid 27226220)
38. Cujec TP, Okamoto H, Fujinaga K et al. The HIV transactivator TAT binds to the CDK-activating kinase and activates the phosphorylation of the carboxy-terminal domain of RNA polymerase II. Genes Dev. 11(20), 2645-2657 (1997). (Pubitemid 27452388)
39. Cujec TP, Cho H, Maldonado E et al. The human immunodeficiency virus transactivator Tat interacts with the RNA polymerase II holoenzyme. Mol. Cell. Biol. 17(4), 1817-1823 (1997).
40. Parada, CA, Roeder RG. Enhanced processivity of RNA polymerase II triggered by Tat-induced phosphorylation of its carboxy-terminal domain. Nature 384(6607), 375-378 (1996). •• First documentation of the phosphorylation of the RNA polymerase II C-terminal domain via HIV-1 Tat interactions.
41. Zhou C Rana TM. A bimolecular mechanism of HIV-1 Tat protein interaction with RNA polymerase II transcription elongation complexes. J. Mol. Biol. 320(5), 925-942 (2002).
42. Chen D, Zhou Q. Tat activates human immunodeficiency virus type 1 transcriptional elongation independent of TFIIH kinase. Mol. Cell. Biol. 19(4), 2863-2871 (1999). (Pubitemid 29144530)
43. Wei P, Garber ME, Fang SM, Fischer WH, Jones KA. A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA. Cell 92(4), 451-462 (1998). (Pubitemid 28101109)
44. Wimmer J, Fujinaga K, Taube R et al. Interactions between Tat and TAR and human immunodeficiency virus replication are facilitated by human cyclin T1 but not cyclins T2a or T2b. Virology 255(1), 182-189 (1999). (Pubitemid 29391706)
45. Zhou M, Halanski MA, Radonovich MF et al. Tat modifies the activity of CDK9 to phosphorylate serine 5 of the RNA polymerase II carboxyl-terminal domain during human immunodeficiency virus type 1 transcription. Mol. Cell. Biol. 20(14), 5077-5086 (2000). (Pubitemid 30431561)
46. Isel, C, Karn J. Direct evidence that HIV-1 Tat stimulates RNA polymerase II carboxyl-terminal domain hyperphosphorylation during transcriptional elongation. J. Mol. Biol. 290(5), 929-941 (1999). (Pubitemid 29371730)
47. Zhou M, Deng L, Lacoste V et al. Coordination of transcription factor phosphorylation and histone methylation by the P-TEFb kinase during human immunodeficiency virus type 1 transcription. J. Virol. 78(24), 13522-13533 (2004). (Pubitemid 39612752)
48. Nguyen VT, Kiss T, Michels AA, Bensaude O. 7SK small nuclear RNA binds to and inhibits the activity of CDK9/cyclin T complexes. Nature 414(6861), 322-325 (2001). (Pubitemid 33097810)
49. Michels AA, Nguyen VT, Fraldi A et al. MAQ1 and 7SK RNA interact with CDK9/cyclin T complexes in a transcription-dependent manner. Mol. Cell. Biol. 23(14), 4859-4869 (2003). (Pubitemid 36793332)
50. Yang Z, Zhu Q, Luo K, Zhou Q. The 7SK small nuclear RNA inhibits the CDK9/cyclin T1 kinase to control transcription. Nature 414(6861), 317-322 (2001). (Pubitemid 33097809)
51. Yik JH, Chen R, Nishimura R, Jennings JL, Link AJ, Zhou Q. Inhibition of P-TEFb (CDK9/cyclin T) kinase and RNA polymerase II transcription by the coordinated actions of HEXIM1 and 7SK snRNA. Mol. Cell. 12(4), 971-982 (2003). (Pubitemid 37352789)
52. Yang Z, Yik JH, Chen R et al. Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4. Mol. Cell. 19(4), 535-545 (2005). (Pubitemid 41140010)
53. Michels AA, Fraldi A, Li Q et al. Binding of the 7SK snRNA turns the HEXIM1 protein into a P-TEFb (CDK9/cyclin T) inhibitor. EMBO J. 23(13), 2608-2619 (2004). (Pubitemid 38988232)
54. Fraldi A, Varrone F, Napolitano G et al. Inhibition of Tat activity by the HEXIM1 protein. Retrovirology 2, 42 (2005). (Pubitemid 41522420)
55. Barboric M, Yik JH, Czudnochowski N et al. Tat competes with HEXIM1 to increase the active pool of P-TEFb for HIV-1 transcription. Nucleic Acids Res. 35(6), 2003-2012 (2007). (Pubitemid 47061666)
56. Peng J, Zhu Y, Milton JT, Price DH. Identification of multiple cyclin subunits of human P-TEFb. Genes Dev. 12(5), 755-762 (1998). (Pubitemid 28134306)
57. Price DH. P-TEFb, a cyclin-dependent kinase controlling elongation by RNA polymerase II. Mol. Cell. Biol. 20(8), 2629-2634 (2000).
58. Napolitano G, Licciardo P, Gallo P, Majello B, Giordano A, Lania L. The CDK9-associated cyclins T1 and T2 exert opposite effects on HIV-1 Tat activity. AIDS 13(12), 1453-1459 (1999). (Pubitemid 29396675)
59. Urano E, Shimizu S, Futahashi Y et al. Cyclin K/CPR4 inhibits primate lentiviral replication by inactivating Tat/positive transcription elongation factor b-dependent long terminal repeat transcription. AIDS 22(9), 1081-1083 (2008). (Pubitemid 351769748)
60. Garber ME, Wei P, KewalRamani VN et al. The interaction between HIV-1 Tat and human cyclin T1 requires zinc and a critical cysteine residue that is not conserved in the murine CycT1 protein. Genes Dev. 12(22), 3512-3527 (1998). (Pubitemid 28553243)
61. Brady J, Kashanchi F. Tat gets the "green" light on transcription initiation. Retrovirology 2, 69 (2005).
62. Kashanchi F, Piras G, Radonovich MF et al. Direct interaction of human TFIID with the HIV-1 transactivator tat. Nature 367(6460), 295-299 (1994). (Pubitemid 2021746)
63. Majello B, Napolitano G, Lania L. Recruitment of the TATA-binding protein to the HIV-1 promoter is a limiting step for Tat transactivation. AIDS 12(15), 1957-1964 (1998).
64. Veschambre P, Simard P, Jalinot P. Evidence for functional interaction between the HIV-1 Tat transactivator and the TATA box binding protein in vivo. J. Mol. Biol. 250(2), 169-180 (1995).
65. Raha T, Cheng SW, Green MR. HIV-1 Tat stimulates transcription complex assembly through recruitment of TBP in the absence of TAFs. PLoS Biol. 3(2), E44 (2005). (Pubitemid 40412642)
66. Mavankal G, Ignatius Ou SH, Oliver H, Sigman D, Gaynor RB. Human immunodeficiency virus type 1 and 2 Tat proteins specifically interact with RNA polymerase II. Proc. Natl Acad. Sci. USA 93(5), 2089-2094 (1996). (Pubitemid 26079885)
67. Ping YH, Rana TM. Tat-associated kinase (P-TEFb): a component of transcription preinitiation and elongation complexes. J. Biol. Chem. 274(11), 7399-7404 (1999).
68. Montanuy I, Torremocha R, Hernández-Munain C, Suñé C. Promoter influences transcription elongation: TATA-box element mediates the assembly of processive transcription complexes responsive to cyclin-dependent kinase 9. J. Biol. Chem. 283(12), 7368-7378 (2008).
69. Jeang KT, Chun R, Lin NH, Gatignol A, Glabe CG, Fan H. In vitro and in vivo binding of human immunodeficiency virus type 1 Tat protein and Sp1 transcription factor. J. Virol. 67(10), 6224-6233 (1993). (Pubitemid 23277534)
70. Deng L, de la Fuente C, Fu P et al. Acetylation of HIV-1 Tat by CBP/P300 increases transcription of integrated HIV-1 genome and enhances binding to core histones. Virology 277(2), 278-295 (2000).
71. Roof P, Ricci M, Genin P et al. Differential regulation of HIV-1 clade-specific B C, and E long terminal repeats by NF-kB and the Tat transactivator. Virology 296(1), 77-83 (2002). (Pubitemid 34936767)
72. Pumfery A, Deng L, Maddukuri A et al. Chromatin remodeling and modification during HIV-1 Tat-activated transcription. Curr. HIV Res. 1(3), 343-362 (2003). • Comprehensive review of chromatin remodeling, epigenetics and HIV-1 transcription.
73. Bukrinsky M. SNFing HIV transcription. Retrovirology 3, 49 (2006).
74. Deng L, Wang D, de la Fuente C et al. Enhancement of the p300 HAT activity by HIV-1 Tat on chromatin DNA. Virology 289(2), 312-326 (2001). (Pubitemid 33141010)
75. Kaehlcke K, Dorr A, Hetzer-Egger C et al. Acetylation of Tat defines a cyclinT1-independent step in HIV transactivation. Mol. Cell. 12(1), 167-176 (2003). (Pubitemid 36945045)
76. Agbottah E, Deng L, Dannenberg LO, Pumfery A, Kashanchi F. Effect of SWI/SNF chromatin remodeling complex on HIV-1 Tat activated transcription. Retrovirology 3, 48 (2006). (Pubitemid 44472637)
77. Mahmoudi T, Parra M, Vries RG et al. The SWI/SNF chromatin-remodeling complex is a cofactor for Tat transactivation of the HIV promoter. J. Biol. Chem. 281(29), 19960-19968 (2006). (Pubitemid 44065769)
78. Ariumi Y, Serhan F, Turelli P, Telenti A, Trono D. The integrase interactor 1 (INI1) proteins facilitate Tat-mediated human immunodeficiency virus type 1 transcription. Retrovirology 3, 47 (2006). (Pubitemid 44309031)
79. Pagans S, Pedal A, North BJ et al. SIRT1 regulates HIV transcription via Tat deacetylation. PLoS Biol. 3(2), E41 (2005). (Pubitemid 40412641)
80. Pagans S, Pedal A, North BJ et al. The β-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 85(7), 1135-1148 (1996).
81. Doranz BJ, Rucker J, Yi Y et al. A dual-tropic primary HIV-1 isolate that uses fusin and the b-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 85(7), 1149-1158 (1996). (Pubitemid 26235280)
82. Hatse S, Princen K, Bridger G, De Clercq E, Schols D. Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4. FEBS Lett. 527(1-3), 255-262 (2002). (Pubitemid 35253875)
83. O'Brien MC, Ueno T, Jahan N, Zajac-Kaye M, Mitsuya H. HIV-1 expression induced by anti-cancer agents in latently HIV-1-infected ACH2 cells. Biochem. Biophys. Res. Commun. 207(3), 903-909 (1995).
84. 2+ mobilization after CD3 stimulation. J. Immunol. 147(9), 3145-3148 (1991).
85. Jordan A, Bisgrove D, Verdin E. HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. EMBO J. 22(8), 1868-1877 (2003).
86. Williams SA, Chen LF, Kwon H, Ruiz-Jarabo CM, Verdin E, Greene WC. NF-κB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation. EMBO J. 25(1), 139-149 (2006). (Pubitemid 43077303)
87. Kim YK, Bourgeois CF, Pearson R et al. Recruitment of TFIIH to the HIV LTR is a rate-limiting step in the emergence of HIV from latency. EMBO J. 25(15), 3596-3604 (2006). (Pubitemid 44264870)
88. Swiggard WJ, Baytop C, Yu JJ et al. Human immunodeficiency virus type 1 can establish latent infection in resting CD4+ T cells in the absence of activating stimuli. J. Virol. 79(22), 14179-14188 (2005). (Pubitemid 41552716)
89. Jeeninga RE, Westerhout EM, van Gerven ML, Berkhout B. HIV-1 latency in actively dividing human T cell lines. Retrovirology 5, 37 (2008). (Pubitemid 351716000)
90. Ringrose JH, Jeeninga RE, Berkhout B, Speijer D. Proteomic studies reveal coordinated changes in T-cell expression patterns upon infection with human immunodeficiency virus type 1. J. Virol. 82(9), 4320-4330 (2008). (Pubitemid 351563669)
91. + cell proteome: dysregulated cell cycle progression and nuclear transport coincide with robust virus production. J. Virol. 81(14), 7571-7583 (2007).
92. Liou LY, Herrmann CH, Rice AP. Transient induction of cyclin T1 during human macrophage differentiation regulates human immunodeficiency virus type 1 Tat transactivation function. J. Virol. 76(21), 10579-10587 (2002).
93. Chen R, Yang Z, Zhou Q. Phosphorylated positive transcription elongation factor b (P-TEFb) is tagged for inhibition through association with 7SK snRNA. J. Biol. Chem. 279(6), 4153-4160 (2004). (Pubitemid 38199000)
94. 2+ signaling. Genes Dev. 22(10), 1356-1368 (2008).
95. Ammosova T, Washington K, Debebe Z, Brady J, Nekhai S. Dephosphorylation of CDK9 by protein phosphatase 2A and protein phosphatase-1 in Tat-activated HIV-1 transcription. Retrovirology 2, 47 (2005). (Pubitemid 41522416)
96. Haaland RE, Herrmann CH, Rice AP. Increased association of 7SK snRNA with Tat cofactor P-TEFb following activation of peripheral blood lymphocytes. AIDS 17(17), 2429-2436 (2003).
97. Rohr O, Marban C, Aunis D, Schaeffer E. Regulation of HIV-1 gene transcription: from lymphocytes to microglial cells. J. Leukoc. Biol. 74(5), 736-749 (2003). (Pubitemid 38040350)
98. Henderson AJ Zou X, Calame KL. C/EBP proteins activate transcription from the human immunodeficiency virus type 1 long terminal repeat in macrophages/monocytes. J. Virol. 69(9), 5337-5344 (1995).
99. Tesmer VM, Rajadhyaksha A, Babin J, Bina M. NF-IL6-mediated transcriptional activation of the long terminal repeat of the human immunodeficiency virus type 1. Proc. Natl Acad. Sci. USA 90(15), 7298-7302 (1993). (Pubitemid 23222437)
100. Mameli G, Deshmane SL, Ghafouri M et al. C/EBPb regulates human immunodeficiency virus 1 gene expression through its association with CDK9. J. Gen. Virol. 88(Pt 2), 631-640 (2007). (Pubitemid 46210903)
101. Ambrosino C, Ruocco MR, Chen X et al. HIV-1 Tat induces the expression of the interleukin-6 (IL6) gene by binding to the IL6 leader RNA and by interacting with CAAT enhancer-binding protein β (NF-IL6) transcription factors. J. Biol. Chem. 272(23), 14883-14892 (1997). (Pubitemid 27251759)
102. Coyle-Rink J, Sweet T, Abraham S et al. Interaction between TGFβ signaling proteins and C/EBP controls basal and Tat-mediated transcription of HIV-1 LTR in astrocytes. Virology 299(2), 240-247 (2002). (Pubitemid 35356600)
103. Brès V, Kiernan RE, Linares LK et al. A non-proteolytic role for ubiquitin in Tat-mediated transactivation of the HIV-1 promoter. Nat. Cell. Biol. 5(8), 754-761 (2003). (Pubitemid 36986784)
104. Boulanger MC, Liang C, Russell RS et al. Methylation of Tat by PRMT6 regulates human immunodeficiency virus type 1 gene expression. J. Virol. 79(1), 124-131 (2005). (Pubitemid 39648370)
105. Van Duyne R, Easley R, Wu W et al. Lysine methylation of HIV-1 Tat regulates transcriptional activity of the viral LTR. Retrovirology 5, 40 (2008). (Pubitemid 351803828)
106. Yu L, Loewenstein PM, Zhang Z, Green M. In vitro interaction of the human immunodeficiency virus type 1 Tat transactivator and the general transcription factor TFIIB with the cellular protein TAP. J. Virol. 69(5), 3017-3023 (1995).
107. Kiernan RE, Vanhulle C, Schiltz L et al. HIV-1 tat transcriptional activity is regulated by acetylation. EMBO J. 18(21), 6106-6118 (1999). (Pubitemid 29515686)
108. Ott M, Schnölzer M, Garnica J et al. Acetylation of the HIV-1 Tat protein by p300 is important for its transcriptional activity. Curr. Biol. 9(24), 1489-1492 (1999). • Demonstration of the regulation of Tat transactivation via acetylation by p300 and recruitment of other cellular proteins. (Pubitemid 30023485)
109. Peterlin BM, Price DH. Controlling the elongation phase of transcription with P-TEFb. Mol. Cell. 23(3), 297-305 (2006).
110. Tréand C, du Chéné I, Brès V et al. Requirement for SWI/SNF chromatin-remodeling complex in Tat-mediated activation of the HIV-1 promoter. EMBO J. 25(8), 1690-1699 (2006).
111. Xie B, Invernizzi CF, Richard S, Wainberg MA. Arginine methylation of the human immunodeficiency virus type 1 Tat protein by PRMT6 negatively affects Tat Interactions with both cyclin T1 and the Tat transactivation region. J. Virol. 81(8), 4226-4234 (2007). (Pubitemid 46586916)
112. Ammosova T, Berro R, Jerebtsova M et al. Phosphorylation of HIV-1 Tat by CDK2 in HIV-1 transcription. Retrovirology 3, 78 (2006). (Pubitemid 44773858)
113. Berro R, de la Fuente C, Klase Z et al. Identifying the membrane proteome of HIV-1 latently infected cells. J. Biol. Chem. 282(11), 8207-8218 (2007). (Pubitemid 47093557)
114. Kadiu I, Wang T, Schlautman JD et al. HIV-1 transforms the monocyte plasma membrane proteome. Cell. Immunol. 258(1), 44-58 (2009).
115. Liang WS, Maddukuri A, Teslovich TM et al. Therapeutic targets for HIV-1 infection in the host proteome. Retrovirology 2, 20 (2005). (Pubitemid 40617960)
116. Gautier VW, Gu L, O'Donoghue N, Pennington S, Sheehy N, Hall WW. In vitro nuclear interactome of the HIV-1 Tat protein. Retrovirology 6(1), 47 (2009).
117. Agbottah E, de La Fuente C, Nekhai S et al. Antiviral activity of CYC202 in HIV-1-infected cells. J. Biol. Chem. 280(4), 3029-3042 (2005). (Pubitemid 40189413)
118. The HIV-1 Human Protein Interaction Database www.ncbi.nlm.nih.gov/RefSeq/ HIVInteractions